Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract manufacturing and formulation services. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone856-697-1441
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$65.86 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Teligent (NASDAQ:TLGT) Frequently Asked Questions
What is Teligent's stock symbol?
Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How were Teligent's earnings last quarter?
Teligent Inc (NASDAQ:TLGT) posted its quarterly earnings data on Monday, March, 18th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.16. The firm had revenue of $16.78 million for the quarter, compared to the consensus estimate of $17.73 million. Teligent had a negative return on equity of 71.90% and a negative net margin of 66.08%. View Teligent's Earnings History.
When is Teligent's next earnings date?
What guidance has Teligent issued on next quarter's earnings?
Teligent updated its FY 2019 earnings guidance on Monday, March, 18th. The company provided EPS guidance of for the period. The company issued revenue guidance of $72.5 million, compared to the consensus revenue estimate of $83.88 million.Teligent also updated its guidance to EPS.
What price target have analysts set for TLGT?
2 equities research analysts have issued 1-year price objectives for Teligent's shares. Their predictions range from $3.00 to $3.00. On average, they expect Teligent's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 240.9% from the stock's current price. View Analyst Price Targets for Teligent.
What is the consensus analysts' recommendation for Teligent?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teligent.
Has Teligent been receiving favorable news coverage?
Headlines about TLGT stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teligent earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.
Who are some of Teligent's key competitors?
Some companies that are related to Teligent include Recro Pharma (REPH), Arbutus Biopharma (ABUS), Nature's Sunshine Products (NATR), Paratek Pharmaceuticals (PRTK), Edge Therapeutics (EDGE), Adamas Pharmaceuticals (ADMS), AgeX Therapeutics (AGE), Menlo Therapeutics (MNLO), Zynerba Pharmaceuticals (ZYNE), Aratana Therapeutics (PETX), REDHILL BIOPHAR/S (RDHL), BELLUS Health (BLUSF), Galmed Pharmaceuticals (GLMD), Newron Pharmaceuticals (NWPHF) and Cue Biopharma (CUE).
What other stocks do shareholders of Teligent own?
Who are Teligent's key executives?
Teligent's management team includes the folowing people:
- Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
- Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
- Mr. Martin Wilson, Gen. Counsel (Age 42)
- Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
- Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)
Who are Teligent's major shareholders?
Teligent's stock is owned by a number of of retail and institutional investors. Top institutional investors include Sanders Morris Harris LLC (3.90%). Company insiders that own Teligent stock include Carole Ben-Maimon, Damian Finio, Jason Grenfell-Gardner, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Institutional Ownership Trends for Teligent.
Which major investors are buying Teligent stock?
TLGT stock was acquired by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. Company insiders that have bought Teligent stock in the last two years include Carole Ben-Maimon, Damian Finio, Jenniffer Collins, Stephen Richardson and Steven H Koehler. View Insider Buying and Selling for Teligent.
How do I buy shares of Teligent?
Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teligent's stock price today?
One share of TLGT stock can currently be purchased for approximately $0.88.
How big of a company is Teligent?
Teligent has a market capitalization of $47.32 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.
What is Teligent's official website?
How can I contact Teligent?
Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]
MarketBeat Community Rating for Teligent (NASDAQ TLGT)
MarketBeat's community ratings are surveys of what our community members think about Teligent and other stocks. Vote "Outperform" if you believe TLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
